Skip to main content

Lin Shao-Lee

In the past year, 1 open-market sale filing worth $1.61M and no purchases.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
$1.61M
1 filing
Net
−$1.61M
Bought minus sold
Companies
1
With open-market trades

Trades

Every Form 4 that lists Lin Shao-Lee as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

CUE Cue Biopharma, Inc.

Chief Executive Officer1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 14, 2026 (view filing)8:46 PM ETAug 12-132 daysLin Shao-LeeChief Executive OfficerSSale−58.3K$27.58−$1.61M−7.6%706.0K after5 lots

SLRN ACELYRIN, Inc.

Chief Executive Officer3 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 3, 2024 (view filing)Apr 12 daysLin Shao-LeeChief Executive OfficerSSale−9.96K$6.63−$66.0K−0.6%1.58M after
Feb 22, 2024 (view filing)Feb 202 daysLin Shao-LeeChief Executive OfficerSSale−15.7K$7.60−$119.3K−1.0%1.59M after
Jan 4, 2024 (view filing)Jan 22 daysLin Shao-LeeChief Executive OfficerSSale−10.7K$7.41−$79.2K−0.7%1.60M after